Teva Pharmaceutical Industries (TEVA)
(Delayed Data from NYSE)
$17.51 USD
-0.25 (-1.41%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $17.51 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth A Momentum A VGM
Balance Sheet
Fiscal Year End for Teva Pharmaceutical Industries Ltd falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 3,226 | 2,801 | 2,165 | 2,177 | 1,975 |
Receivables | 3,408 | 3,696 | 4,529 | 4,581 | 5,676 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 4,021 | 3,833 | 3,818 | 4,403 | 4,422 |
Other Current Assets | 1,829 | 1,721 | 2,059 | 1,844 | 1,391 |
Total Current Assets | 12,485 | 12,051 | 12,573 | 13,005 | 13,464 |
Net Property & Equipment | 5,750 | 5,739 | 5,982 | 6,296 | 6,436 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 1,812 | 1,453 | 596 | 695 | 386 |
Intangibles | 22,564 | 23,903 | 27,506 | 29,547 | 36,078 |
Deposits & Other Assets | 470 | 441 | 515 | 538 | 591 |
Total Assets | 43,479 | 44,006 | 47,666 | 50,640 | 57,470 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 2,602 | 1,887 | 1,686 | 1,756 | 1,718 |
Current Portion Long-Term Debt | 1,672 | 2,109 | 1,426 | 3,188 | 2,345 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 3,382 | 2,717 | 2,771 | 2,465 | 2,562 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 4,591 | 4,755 | 5,144 | 5,757 | 7,048 |
Total Current Liabilities | 12,247 | 11,469 | 11,027 | 13,164 | 13,674 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 606 | 548 | 784 | 964 | 1,096 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 18,161 | 19,103 | 21,617 | 22,731 | 24,562 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 4,019 | 3,847 | 2,578 | 2,240 | 2,640 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 35,353 | 35,315 | 36,422 | 39,579 | 42,407 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 57 | 57 | 57 | 57 | 56 |
Capital Surplus | 27,807 | 27,688 | 27,561 | 27,443 | 27,312 |
Retained Earnings | -13,534 | -12,882 | -10,529 | -10,946 | -6,956 |
Other Equity | -2,077 | -2,044 | -1,717 | -1,364 | -1,221 |
Treasury Stock | 4,128 | 4,128 | 4,128 | 4,128 | 4,128 |
Total Shareholder's Equity | 8,126 | 8,691 | 11,244 | 11,061 | 15,063 |
Total Liabilities & Shareholder's Equity | 43,479 | 44,006 | 47,666 | 50,640 | 57,470 |
Total Common Equity | 8,126 | 8,691 | 11,244 | 11,061 | 15,063 |
Shares Outstanding | 1,121.00 | 1,110.90 | 1,103.30 | 1,092.10 | 1,092.10 |
Book Value Per Share | 7.25 | 7.82 | 10.19 | 10.13 | 13.79 |
Fiscal Year End for Teva Pharmaceutical Industries Ltd falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 2,258 | 2,991 | 3,226 | 2,249 | 2,669 |
Receivables | 3,766 | 3,456 | 3,408 | 3,385 | 3,539 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 3,927 | 3,949 | 4,021 | 4,051 | 4,109 |
Other Current Assets | 1,682 | 1,901 | 1,829 | 1,739 | 1,770 |
Total Current Assets | 11,632 | 12,297 | 12,485 | 11,425 | 12,088 |
Net Property & Equipment | 5,573 | 5,618 | 5,750 | 5,622 | 5,712 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 2,000 | 1,960 | 1,812 | 1,748 | 1,578 |
Intangibles | 21,341 | 22,063 | 22,564 | 22,410 | 22,856 |
Deposits & Other Assets | 434 | 470 | 470 | 477 | 443 |
Total Assets | 41,338 | 42,773 | 43,479 | 42,088 | 43,095 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 2,366 | 2,439 | 2,602 | 2,280 | 2,508 |
Current Portion Long-Term Debt | 2,094 | 3,060 | 1,672 | 1,479 | 1,980 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 3,332 | 3,276 | 3,382 | 3,271 | 2,949 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 5,247 | 5,017 | 4,591 | 4,362 | 4,406 |
Total Current Liabilities | 13,037 | 13,792 | 12,247 | 11,394 | 11,843 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 553 | 569 | 606 | 544 | 534 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 16,547 | 16,584 | 18,161 | 18,495 | 18,698 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 4,356 | 4,019 | 3,818 | 3,973 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 34,774 | 35,230 | 35,353 | 34,576 | 35,387 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 58 | 58 | 57 | 57 | 57 |
Capital Surplus | 27,829 | 27,796 | 27,807 | 27,780 | 27,748 |
Retained Earnings | -14,519 | -13,673 | -13,534 | -13,870 | -13,950 |
Other Equity | -2,677 | -2,510 | -2,077 | -2,328 | -2,021 |
Treasury Stock | 4,128 | 4,128 | 4,128 | 4,128 | 4,128 |
Total Shareholder's Equity | 6,563 | 7,543 | 8,126 | 7,512 | 7,708 |
Total Liabilities & Shareholder's Equity | 41,338 | 42,773 | 43,479 | 42,088 | 43,095 |
Total Common Equity | 6,563 | 7,543 | 8,126 | 7,512 | 7,708 |
Shares Outstanding | 1,132.90 | 1,132.60 | 1,121.00 | 1,120.90 | 1,120.60 |
Book Value Per Share | 5.79 | 6.66 | 7.25 | 6.70 | 6.88 |